- ROUNDTABLE: Pharmacy’s future in sync with technology
- Lumene unveils product innovation, new packaging for 2014
- Walgreens partners with United Nations Foundation's Shot@Life campaign
- Vitamins and Supplements 2014
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
ROSEMONT, Pa. — Drug maker Duchesnay USA has launched a new treatment for morning sickness, the company said Tuesday.
The drug maker, which focuses on products for pregnant women, announced the launch of Diclegis (doxylamine succinate 10 mg; pyridoxine hydrochloride [vitamin B6] 10 mg) for morning sickness, known medically as nausea and vomiting of pregnancy, or NVP. According to research, 70-85% of pregnant women experience morning sickness, which despite its name can last throughout the day. The drug received Food and Drug Administration approval last month.
"We believe Diclegis will become an important treatment for healthcare professionals caring for pregnant women with nausea and vomiting of pregnancy," Duchesnay USA CEO Gilbert Godin said. "The product's safety profile and its proven clinical effectiveness make it a convenient and innovative treatment for women who are seeking effective NVP symptom relief."